HUMANIGEN, INC

2023 Q2 Form 10-Q Financial Statement

#000121465923007002 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.096M $68.95M
YoY Change -95.51% -25.77%
Cash & Equivalents $3.096M $68.95M
Short-Term Investments
Other Short-Term Assets $1.930M $2.287M
YoY Change -15.61% 165.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.026M $71.24M
YoY Change -92.94% -27.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K $90.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $90.00K $90.00K
YoY Change 0.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $5.026M $71.24M
Total Long-Term Assets $90.00K $90.00K
Total Assets $5.116M $71.33M
YoY Change -92.83% -27.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.39M $47.87M
YoY Change -19.8% 10.28%
Accrued Expenses $14.02M $19.18M
YoY Change -26.9% 236.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.30M $71.18M
YoY Change -25.13% 33.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $25.19M
YoY Change -100.0% 3.08%
Other Long-Term Liabilities $1.545M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $1.545M $25.19M
YoY Change -93.87% -11.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.30M $71.18M
Total Long-Term Liabilities $1.545M $25.19M
Total Liabilities $54.84M $96.37M
YoY Change -43.1% 17.77%
SHAREHOLDERS EQUITY
Retained Earnings -$686.0M
YoY Change
Common Stock $119.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$49.73M -$25.05M
YoY Change
Total Liabilities & Shareholders Equity $5.116M $71.33M
YoY Change -92.83% -27.85%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
119080135 shares
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14021000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14791000 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
883000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
883000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
40520000 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35798
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0557236
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
830 Morris Turnpike
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Short Hills
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07078
CY2023Q1 dei City Area Code
CityAreaCode
(973)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
200-3100
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
HGEN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119080135 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3096000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10155000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1930000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
950000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
5026000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11105000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000 usd
CY2023Q1 us-gaap Assets
Assets
5116000 usd
CY2022Q4 us-gaap Assets
Assets
11195000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
38392000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
53296000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56194000 usd
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1545000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1766000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
54841000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
57960000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119080135 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119080135 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119080135 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119080135 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
119000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
119000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
636147000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
634925000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-685991000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-681809000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-49725000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-46765000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5116000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11195000 usd
CY2023Q1 us-gaap Revenues
Revenues
221000 usd
CY2022Q1 us-gaap Revenues
Revenues
1036000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
737000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17220000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3719000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4345000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4456000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
21565000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4235000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20529000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
18000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
734000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
71000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4182000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21278000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
119080135 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65590724 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4182000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21278000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1222000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1543000 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
187000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
980000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1332000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2128000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3175000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-770000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-701000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-221000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1036000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7059000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19442000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18374000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18374000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7059000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1068000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10155000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70016000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3096000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68948000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
550000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-46765000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1222000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4182000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-49725000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23688000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18374000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1543000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21278000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25049000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3100000 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
52400000 usd
CY2023Q1 hgen Paid To Avid
PaidToAvid
3000000 usd
CY2023Q1 hgen Loss Contingency Settlement Agreement Expiration
LossContingencySettlementAgreementExpiration
P120D
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
HUMANIGEN, INC
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7208843 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5254883 shares
CY2020Q4 hgen Upfront License Fee Amount
UpfrontLicenseFeeAmount
6000000 usd
CY2021Q1 hgen Milestone License Payments
MilestoneLicensePayments
14000000 usd
CY2021Q2 hgen Milestone License Payments
MilestoneLicensePayments
6000000 usd
CY2021Q2 hgen Net Of Withholding Taxes And Other Fees And Royalties
NetOfWithholdingTaxesAndOtherFeesAndRoyalties
4500000 usd
CY2023Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
It is expected that the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
CY2023Q1 hgen Upfront License Fee Amount
UpfrontLicenseFeeAmount
6000000 usd
CY2023Q1 hgen Net Of Withholding Taxes And Other Fees And Royalties
NetOfWithholdingTaxesAndOtherFeesAndRoyalties
4500000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
800000 usd
CY2023Q1 hgen Revenue From Contracts With Customer Including Assessed Tax
RevenueFromContractsWithCustomerIncludingAssessedTax
200000 usd
CY2022Q1 hgen Revenue From Contracts With Customer Including Assessed Tax
RevenueFromContractsWithCustomerIncludingAssessedTax
1000000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
1800000 usd
CY2022Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5926748 shares
CY2022Q1 hgen Net Proceeds From Common Stock
NetProceedsFromCommonStock
18400000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7472056 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.23
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
294451 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.43
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7177605 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.14
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1222000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1543000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4700000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65590724 shares
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001293310

Files In Submission

Name View Source Status
0001214659-23-007002-index-headers.html Edgar Link pending
0001214659-23-007002-index.html Edgar Link pending
0001214659-23-007002.txt Edgar Link pending
0001214659-23-007002-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hgen-20230331.htm Edgar Link pending
hgen-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
pipeline.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hgen-20230331_def.xml Edgar Link unprocessable
hgen-20230331_cal.xml Edgar Link unprocessable
hgen-20230331_lab.xml Edgar Link unprocessable
hgen-20230331_pre.xml Edgar Link unprocessable
hgen-20230331_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending